Status:
UNKNOWN
Personalized Neurorehabilitative Precision Medicine - From Data to Therapies
Lead Sponsor:
University Hospital Tuebingen
Collaborating Sponsors:
Interfaculty Institute for Biomedical Informatics (IBMI)
Cluster of Excellence - Machine Learning for Science
Conditions:
Stroke, Acute
Outcome, Improvement
Eligibility:
All Genders
18+ years
Brief Summary
Stroke is the most common neurological disease leaving one third dead and one third with permanent impairment despite best medical treatment. The aim of the present study is to investigate why patient...
Detailed Description
Clinical tests: Each subject will be assessed using the following tests: National Institute of Health Stroke Scale (NIHSS): The NIHSS is part of the usual highly standardized stroke workup. It consis...
Eligibility Criteria
Inclusion
- Subject is 18 years or above.
- Subject has an acute stroke affecting one UE (FMA less than 50).
- Subject or understands the study and its procedures and gives informed consent.
- If the subject is not able to give informed consent:
- The assumed will of the patient is to be determined by the patient's provision (if existing), the health care proxy (if existing) and/or the moral concepts expressed by the patient to close relatives.
- The legal representative gives informed consent because participation is the assumed will of the patient as assessed by the aforementioned points.
Exclusion
- Subject is less than 18 years old.
- The subject does not have an acute stroke, or stroke does not affect the UE, or FMA \> 50.
- Subject or legal representative cannot give informed consent.
- Patient has an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head (excluding the mouth) that cannot be safely removed.
- Subject has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- There is any concern by the investigator regarding the safe participation of the subject in the study, or for any other reason the investigator considers the subject inappropriate for participation in the study.
- Subject is pregnant.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04688970
Start Date
December 1 2020
End Date
June 30 2022
Last Update
December 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital of Tuebingen
Tübingen, Baden-Wurttemberg, Germany, 72076